Infection in Renal Transplant Recipients

Seminars in Nephrology

Volumn 27, Issue 4, 2007, Pages 445-461

  Fishman, Jay A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

donor derived infection; fungus; immunosuppression; opportunistic infection; prophylaxis; Renal transplantation; virus

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ATOVAQUONE; AZATHIOPRINE; CIDOFOVIR; CLOTRIMAZOLE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; FAMCICLOVIR; FLUCONAZOLE; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; LEVOFLOXACIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PENTAMIDINE; PREDNISONE; PYRIMETHAMINE; RAPAMYCIN; SULFAMETHOXAZOLE; TACROLIMUS; TRIMETHOPRIM; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL INFECTION; CENTRAL NERVOUS SYSTEM INFECTION; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE TRANSMISSION; DRUG COST; EPSTEIN BARR VIRUS; FEVER; GINGIVA DISEASE; HEMOLYSIS; HEPATITIS B; HEPATITIS C; HERPES VIRUS INFECTION; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RISK; KIDNEY INFECTION; KIDNEY TRANSPLANTATION; LISTERIA; MEDICAL TECHNOLOGY; MYCOSIS; NEPHROTOXICITY; NEUTROPENIA; NOCARDIA; PATHOGENESIS; PLASMAPHERESIS; PNEUMOCYSTIS; PNEUMONIA; POLYOMA VIRUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCREENING; TOXOPLASMA; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

GRAFT REJECTION; HUMANS; INCIDENCE; INFECTION; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; WORLD HEALTH;

EID: 34347357640     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.03.006     Document Type: Article

References (49)

1. Fishman J.A., and Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 338 (1998) 1741-1751
2. Wilck M., and Fishman J. The challenges of infection in transplantation: donor-derived infections. Curr Opin Organ Transplant 10 (2005) 301-306
3. Schaffner A. Pretransplant evaluation for infections in donors and recipients of solid organs. Clin Infect Dis 33 Suppl 1 (2001) S9-S14
4. Delmonico F.L., and Snydman D.R. Organ donor screening for infectious diseases: review of practice and implications for transplantation. Transplantation 65 (1998) 603-610
5. Delmonico F.L. Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 31 (2000) 781-786
6. Rosengard B.R., Feng S., Alfrey E.J., et al. Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor. Am J Transplant 2 (2002) 701-711
7. Freeman R.B., Giatras I., Falagas M.E., et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 68 (1999) 1107-1111
8. Kasiske B.L., Ravenscraft M., Ramos E.L., Gaston R.S., Bia M.J., Danovitch G.M., and Ad Hoc Clinical Practice Guidelines Subcommittee of the Patient Care and Education Committee of the American Society of Transplant Physicians. The evaluation of living renal transplant donors: clinical practice guidelines. J Am Soc Nephrol 7 (1996) 2288-2313
9. Kasiske B.L., Ramos E.L., Gaston R.S., et al., Patient Care and Education Committee of the American Society of Transplant Physicians. The evaluation of renal transplant candidates: clinical practice guidelines. J Am Soc Nephrol 6 (1995) 1-34
10. Fischer S.A., Graham M.B., Kuehnert M.J., et al. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 354 (2006) 2235-2249
11. Avery R.K. Infections and immunizations in organ transplant recipients: a preventive approach. Cleve Clin J Med 61 (1994) 386-392
12. Avery R.K. Prophylactic strategies before solid-organ transplantation. Curr Opin Infect Dis 17 (2004) 353-356
13. Singh N., and Paterson D.L. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis 27 (1998) 1266-1277
14. Fishman J.A., and Rubin R.H. Solid organ transplantation in HIV-infected individuals: obstacles and opportunities. Transplant Proc 33 (2001) 1310-1314
15. Razonable R.R., and Paya C.V. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10 (2003) 60-65
16. Humar A., Gillingham K., Payne W.D., Sutherland D.E., and Matas A.J. Increased incidence of cardiac complications in kidney transplant recipients with cytomegalovirus disease. Transplantation 70 (2000) 310-313
17. Preiksaitis J.K., Brennan D.C., Fishman J., and Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. [erratum appears in Am J Transplant 2005;5:635]. Am J Transplant 5 (2005) 218-227
18. Prosch S., Wuttke R., Kruger D.H., and Volk H.D. NF-kappaB-a potential therapeutic target for inhibition of human cytomegalovirus (re)activation?. Biol Chem 383 (2002) 1601-1609
19. Fietze E., Prosch S., Reinke P., et al. Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 58 (1994) 675-680
20. Sester M., Sester U., Gartner B., et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71 (2001) 1287-1294
21. Sester M., Sester U., Gartner B.C., Girndt M., Meyerhans A., and Kohler H. Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 13 (2002) 2577-2584
22. Lowance D., Neumayer H.H., Legendre C.M., et al., International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340 (1999) 1462-1470
23. Kalil A.C., Levitsky J., Lyden E., Stoner J., and Freifeld A.G. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 143 (2005) 870-880
24. Humar A., Mazzulli T., Moussa G., et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 5 (2005) 1065-1070
25. Caliendo A.M., Yen-Lieberman B., Baptista J., et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 41 (2003) 3509-3513
26. Humar A., Kumar D., Boivin G., and Caliendo A.M. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186 (2002) 829-833
27. Funch D.P., Walker A.M., Schneider G., Ziyadeh N.J., and Pescovitz M.D. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 5 (2005) 2894-2900
28. Sagedal S., Hartmann A., Nordal K.P., et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 66 (2004) 329-337
29. Harris N.L., Ferry J.A., and Swerdlow S.H. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14 (1997) 8-14
30. Opelz G., and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342 (1993) 1514-1516
31. Paya C.V., Fung J.J., Nalesnik M.A., et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68 (1999) 1517-1525
32. Preiksaitis J.K., and Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 33 Suppl 1 (2001) S38-S46
33. Green M., Michaels M.G., Webber S.A., Rowe D., and Reyes J. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transplant 3 (1999) 271-281
34. Mylonakis E., Goes N., Rubin R.H., Cosimi A.B., Colvin R.B., and Fishman J.A. BK virus in solid organ transplant recipients: an emerging syndrome. Transplantation 72 (2001) 1587-1592
35. Hirsch H.H., and Suthanthiran M. The natural history, risk factors and outcomes of polyomavirus BK-associated nephropathy after renal transplantation. Nat Clin Pract Nephrol 2 (2006) 240-241
36. Drachenberg C.B., Hirsch H.H., Ramos E., and Papadimitriou J.C. Polyomavirus disease in renal transplantation: review of pathological findings and diagnostic methods. Hum Pathol 36 (2005) 1245-1255
37. Hirsch H.H., Brennan D.C., Drachenberg C.B., et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 79 (2005) 1277-1286
38. Hirsch H.H. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2 (2002) 25-30
39. Hirsch H.H., Knowles W., Dickenmann M., et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347 (2002) 488-496
40. Randhawa P., Vats A., and Shapiro R. Monitoring for polyomavirus BK And JC in urine: comparison of quantitative polymerase chain reaction with urine cytology. Transplantation 79 (2005) 984-986
41. Randhawa P., Ho A., Shapiro R., et al. Correlates of quantitative measurement of BK polyomavirus (BKV) DNA with clinical course of BKV infection in renal transplant patients. J Clin Microbiol 42 (2004) 1176-1180
42. Nickeleit V., Klimkait T., Binet I.F., et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 342 (2000) 1309-1315
43. Vats A., Randhawa P.S., and Shapiro R. Diagnosis and treatment of BK virus-associated transplant nephropathy. Adv Exp Med Biol 577 (2006) 213-227
44. Trofe J., Hirsch H.H., and Ramos E. Polyomavirus-associated nephropathy: update of clinical management in kidney transplant patients. Transplant Infect Dis 8 (2006) 76-85
45. Hirsch H.H., and Ramos E. Retransplantation after polyomavirus-associated nephropathy: just do it?. Am J Transplant 6 (2006) 7-9
46. Fishman J.A. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 42 (1998) 995-1004
47. Rodriguez M., and Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 17 (2004) 770-782
48. Fishman J.A. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 33 (2001) 1397-1405
49. Champion L., Stern M., Israel-Biet D., et al. Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. [summary for patients in Ann Intern Med. 2006;144:I45]. Ann Intern Med 144 (2006) 505-509